

2 November 2020

## 2020/21 Invitation to Tender

The 2020/21 Invitation to Tender (2020/21 ITT) has been distributed today.

If you have already registered your e-mail address with PHARMAC's tendering e-portal you can access the 2020/21 ITT in the e-portal in Current Tenders.

If you have not registered your company with the e-Portal, and you would like to participate in the 2020/21 ITT, please register at <https://in-tendhost.co.uk/pharmac.aspx/Home>.

A complete copy of the 2020/21 ITT is available on [our website](#). We will not be posting out any hard copies of the 2020/21 ITT.

If you wish to submit a Tender Bid in relation to community supply and/or hospital supply, you must submit it via the Electronic Portal to PHARMAC no later than **4 pm** (New Zealand time) on **Thursday 17 December 2020**.

### Changes to the 2020/21 ITT product list

Please note that the product list (Schedule Two) consulted on in August 2020 has changed. Some products have been added, removed or amended either as a result of:

- clinical advice received (i.e. from the Tender Medical Evaluation Subcommittee of PTAC); and/or
- consultation responses received from suppliers, DHBs and/or medical groups; and/or
- a review of unresolved bids from previous tenders; and/or
- Alternative Commercial Proposals being progressed by PHARMAC.

The following items have been added to the 2020/21 ITT:

Chemical Name	Line Item
Aciclovir	Eye oint 3%
Aprepitant (current access)	Cap 40 mg
Aprepitant (widened access)	Cap 40 mg
Azacitidine (widened access)	Inj 100 mg
Brimonidine Tartrate with Timolol Maleate	Eye drops 0.2% with timolol maleate 0.5%
Cetirizine hydrochloride	Oral liq 1 mg per ml
Chlorhexidine gluconate	Mouthwash 0.2%
Chlorhexidine with benzydamine	Mouthwash
Cinacalcet (current access)	Tab 60 mg
Cinacalcet (current access)	Tab 90 mg
Cinacalcet (widened access)	Tab 30 mg

Chemical Name	Line Item
Cinacalcet (widened access)	Tab 60 mg
Cinacalcet (widened access)	Tab 90 mg
Diclofenac sodium	Tab EC 25 mg
Diclofenac sodium	Suppos 25 mg
Diclofenac sodium	Suppos 50 mg
Disulfiram	Tab 200 mg
Ferrous Sulphate with Ascorbic Acid	Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg
Fosfomycin (widened access)	Powder
Glycopyrronium bromide	Inj 0.2 mg per ml, 1 ml

Chemical Name	Line Item
Heparin Sodium	Inj 5,000 iu per ml, 5 ml ampoule
Hydrocortisone	Tab 4 mg
Loperamide hydrochloride [split market]	Tab 2 mg
Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride	Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet
Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride	Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet
Mebendazole	Tab 100 mg
Methylprednisolone aceponate	Crn 0.1%
Naproxen	Tab 500 mg
Naproxen	Tab long-acting 1,000 mg
Neostigmine metisulfate	Inj 2.5 mg per ml, 1 ml
Neostigmine metisulfate with glycopyrronium bromide	Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml
Nifedipine	Tab long-acting 10 mg
Nifedipine	Tab long-acting 20 mg
Nifedipine	Tab long-acting 30 mg
Nifedipine	Tab long-acting 60 mg
Noradrenaline	Inj 0.06 mg per ml, 100 ml bag
Noradrenaline	Inj 0.06 mg per ml, 50 ml syringe
Noradrenaline	Inj 0.1 mg per ml, 100 ml bag
Noradrenaline	Inj 0.12 mg per ml, 100 ml bag

Chemical Name	Line Item
Noradrenaline	Inj 0.12 mg per ml, 50 ml syringe
Noradrenaline	Inj 0.16 mg per ml, 100 ml bag
Noradrenaline	Inj 0.16 mg per ml, 50 ml syringe
Noradrenaline	Inj 0.16 mg per ml, 50 ml vial
Noradrenaline	Inj 1 mg per ml, 100 ml bag
Octreotide (somatostatin analogue)	Inj 50 mcg per ml, 1 ml
Octreotide (somatostatin analogue)	Inj 100 mcg per ml, 1 ml
Octreotide (somatostatin analogue)	Inj 500 mcg per ml, 1 ml
Pancreatic enzyme	Cap 150 mg
Pancreatic enzyme	Cap 175 mg
Pancreatic enzyme	Cap 300 mg
Pazopanib (widened access)	Tab 200 mg
Pazopanib (widened access)	Tab 400 mg
Pregnancy tests - HCG urine	Pregnancy test - HCG urine - Dipstick
Pregnancy tests - HCG urine	Pregnancy tests - HCG urine - Cassette
Pregnancy tests - HCG urine	Pregnancy tests - HCG urine - Midstream
Promethazine hydrochloride	Inj 25 mg per ml, 2 ml
Silver Sulphadiazine	Crn 1% (pack size of 100 g or less)
Sodium citrate	Oral liq 8.8% (300 mmol/l)
Somatropin	Inj 7.51 mg per ml - 9 mg per ml, including overage
Sunitinib (widened access)	Cap 12.5 mg
Sunitinib (widened access)	Cap 25 mg
Sunitinib (widened access)	Cap 37.5 mg
Sunitinib (widened access)	Cap 50 mg
Ticagrelor	Tab 90 mg
Tramadol hydrochloride	Oral soln 10 mg per ml
Travoprost	Eye drops 0.004%

Chemical Name	Line Item
Valganciclovir (widened access)	Tab 450 mg
Zopiclone	Tab 3.75 mg (pack size 30 tabs or less)

Chemical Name	Line Item
Zopiclone	Tab 3.75 mg (pack size greater than 30 tablets)

The following items that were included in consultation have been removed from the 2020/21 ITT:

Chemical Name	Line Item
Amoxicillin clavulanate	Grans for oral liq amoxicillin 400 mg with potassium clavulanate 57 mg per 5 ml
Benzbromarone	Tab 100 mg
Budesonide (current access)	Cap modified-release
Budesonide (widened access)	Cap modified-release
Celecoxib	Cap 100 mg
Celecoxib	Cap 200 mg
Clonazepam	Tab 500 mcg
Clonazepam	Tab 2 mg
Dasatinib	Tab 20 mg
Dasatinib	Tab 50 mg
Dasatinib	Tab 70 mg
Etoricoxib	Tab 30 mg
Etoricoxib	Tab 60 mg
Etoricoxib	Tab 90 mg

Chemical Name	Line Item
Etoricoxib	Tab 120 mg
Heparin Sodium	Inj 1,000 iu per ml, 20 - 35 ml
Hydrocortisone Butyrate	Lipocream 0.1% (pack size greater than 30 g)
Metformin Hydrochloride	Tab immediate-release 1 g
Paliperidone	Inj 25 mg
Paliperidone	Inj 50 mg
Paliperidone	Inj 75 mg
Paliperidone	Inj 100 mg
Paliperidone	Inj 150 mg
Phenobarbitone	Tab 15 mg
Phenobarbitone	Tab 30 mg
Posaconazole	Oral liq 40 mg per ml
Rivaroxaban	Tab 10 mg
Rivaroxaban	Tab 15 mg
Rivaroxaban	Tab 20 mg

The following items have been amended in the 2020/21 ITT:

Chemical Name	Line Item
Alpha Tocopheryl Acetate	Oral liq
Aprepitant (current access)	Cap 80 mg
Aprepitant (current access)	Cap 125 mg
Aprepitant (current access)	Cap 165 mg
Aprepitant (current access)	Cap 2 x 80 mg and 1 x 125 mg
Aprepitant (widened access)	Cap 80 mg
Aprepitant (widened access)	Cap 125 mg
Aprepitant (widened access)	Cap 165 mg
Aprepitant (widened access)	Cap 2 x 80 mg and 1 x 125 mg

Chemical Name	Line Item
Atenolol	Tab 50 mg
Atropine sulphate	Inj 600 mcg, 1 ml
Azacitidine (current access)	Inj 100 mg
Benzbromarone	Tab 25 - 100 mg
Cefepime	Inj 1 g
Cefepime	Inj 2 g
Cefoxitin	Inj 1 g
Cinacalcet (current access)	Tab 30 mg
Dexamethasone	Tab 0.5 mg - 1 mg
Diclofenac sodium	Tab EC 50 mg
Diclofenac sodium	Suppos 12.5 mg

Chemical Name	Line Item
Enoxaparin sodium	Inj 20 mg per 0.2 ml
Enoxaparin sodium	Inj 40 mg per 0.4 ml
Enoxaparin sodium	Inj 60 mg per 0.6 ml
Enoxaparin sodium	Inj 80 mg per 0.8 ml
Enoxaparin sodium	Inj 100 mg per ml, 1 ml
Enoxaparin sodium	Inj 120 mg per 0.8 ml
Enoxaparin sodium	Inj 150 mg per ml, 1 ml
Eplerenone (widened access)	Tab 25 mg
Fosfomycin (current access)	Powder
Gentamicin sulphate	Inj 10 mg per ml, 1 - 2 ml
Hydrocortisone Butyrate	Cream 0.1% (pack size 30 g or less)
Ketamine	Inj 100 mg per ml, 2 ml
Lanreotide	Inj 60 mg per 0.5 ml, 0.5 ml syringe
Lanreotide	Inj 90 mg per 0.5 ml, 0.5 ml syringe
Lanreotide	Inj 120 mg per 0.5 ml, 0.5 ml syringe
Methadone hydrochloride	Oral liq 2 mg per ml
Methadone hydrochloride	Oral liq 5 mg per ml
Methadone hydrochloride	Oral liq 10 mg per ml
Metronidazole	Gel 0.75%
Miconazole	Oral gel 20 mg per g
Morphine Hydrochloride	Oral liq 1 mg per ml
Morphine Hydrochloride	Oral liq 2 mg per ml
Morphine Hydrochloride	Oral liq 5 mg per ml
Morphine Hydrochloride	Oral liq 10 mg per ml

Chemical Name	Line Item
Naproxen	Tab 250 mg
Naproxen	Tab long-acting 750 mg
Netupitant with Palonosetron	Cap netupitant 300 mg with palonosetron 500 mcg
Octreotide (somatostatin analogue) (current access)	LAR 10 mg pre-filled syringe
Octreotide (somatostatin analogue) (current access)	LAR 20 mg pre-filled syringe
Octreotide (somatostatin analogue) (current access)	LAR 30 mg pre-filled syringe
Octreotide (somatostatin analogue) (widened access)	LAR 10 mg pre-filled syringe
Octreotide (somatostatin analogue) (widened access)	LAR 20 mg pre-filled syringe
Octreotide (somatostatin analogue) (widened access)	LAR 30 mg pre-filled syringe
Pazopanib (current access)	Tab 200 mg
Pazopanib (current access)	Tab 400 mg
Risperidone	Inj 25 mg
Risperidone	Inj 37.5 mg
Risperidone	Inj 50 mg
Somatropin	Inj 5.51 mg per ml - 7.5 mg per ml, including overage
Sunitinib (current access)	Cap 12.5 mg
Sunitinib (current access)	Cap 25 mg
Sunitinib (current access)	Cap 37.5 mg
Sunitinib (current access)	Cap 50 mg
Valganciclovir (current access)	Tab 450 mg

## Appropriate pack-size and packaging type

Where possible, PHARMAC has identified Tender Items where there is a specific product preference in Schedule Two of the 2020/21 ITT document. For example (highlighted in red):

Chemical Name	Quantity	Value	Unit Price	Category	Preference
<b>Cetomacrogol</b>					
Crm BP	64,334,503	\$319,099	\$0.0050	C H	5%
Crm BP (100 g or less)				H	5% Preference for a tube pack.
<b>Chlorhexidine gluconate</b>					
Mouthwash 0.2%	5,714,100	\$73,426	\$0.0129	C H	5% Preference for alcohol free product Not currently listed.

While PHARMAC has taken all reasonable care in identifying these preferences, it makes no representation as to the accuracy of this information and accepts no liability for any errors or omissions. Suppliers should always undertake their own due diligence before submitting any tender bids.

## Oncology injectables

DHBs are increasingly delivering chemotherapy treatment in satellite centers which require compounded products to have a shelf-life greater than 24 hours to account for delays in treatment transport and delivery. Due to this PHARMAC has indicated a preference for products where stability data post-compounding is greater than 48 hours.

## Ophthalmology Products (BAK-free)

For a number of Ophthalmology products, as indicated in Schedule Two of the 2020/21 ITT, PHARMAC reserves its right to list a benzalkonium chloride (BAK) or preservative-free product for a restricted market. However, where a tender product is BAK-free it would have the entire market.

## Somatropin

PHARMAC have included Schedule Seven in the 2020/21 ITT relating to special terms for the supply of somatropin injections. PHARMAC would require the Principal Supplier of somatropin injections to provide education, training and support resources and related products at no cost.

## Access criteria

For a number of products, as indicated in Schedule Two of the 2020/21 ITT document, there is either no funded product on the Pharmaceutical Schedule or PHARMAC is tendering for current and/or widened access. Where clinical advice has been received regarding potential access criteria, links to this advice have been included below. Please note any access criteria stated via the links is indicative only and PHARMAC reserves the right to amend these criteria.

Chemical Name	Line Item(s)
<a href="#">Alpha tocopheryl acetate</a>	Oral liq
<a href="#">Aprepitant (current access)</a>	Cap 40 mg Cap 80 mg Cap 125 mg Cap 165 mg
<a href="#">Aprepitant (widened access)</a>	Cap 40 mg Cap 80 mg Cap 125 mg Cap 165 mg Cap 2 x 80 mg and 1 x 125 mg

Chemical Name	Line Item(s)
<a href="#">Azacitidine (widened access)</a>	Inj 100 mg
<a href="#">Cinacalcet (current access)</a>	Tab 60 mg Tab 90 mg
<a href="#">Cinacalcet (widened access)</a>	Tab 30 mg Tab 60 mg Tab 90 mg
<a href="#">Efavirenz</a>	Tab 50 mg
<a href="#">Eplerenone (widened access)</a>	Tab 25 mg Tab 50 mg
<a href="#">Fosfomycin</a>	Powder

Chemical Name	Line Item(s)
<a href="#">Lanreotide</a>	Inj 60 mg per 0.5 ml, 0.5 ml syringe Inj 90 mg per 0.5 ml, 0.5 ml syringe Inj 120 mg per 0.5 ml, 0.5 ml syringe
<a href="#">Metronidazole</a>	Gel 0.75%
<a href="#">Netupitant with palonosetron</a>	Cap netupitant 300 mg with palonosetron 500 mcg
<a href="#">Octreotide (somatostatin analogue) (widened access)</a>	LAR 10 mg pre-filled syringe LAR 20 mg pre-filled syringe LAR 30 mg pre-filled syringe
<a href="#">Pazopanib (widened access)</a>	Tab 200 mg

Chemical Name	Line Item(s)
	Tab 400 mg
<a href="#">Potassium citrate</a>	Tab
<a href="#">Somatropin</a>	Inj 0.05 mg per ml – 2.5 mg per ml, including overage Inj 5.51 mg per ml – 9 mg per ml, including overage
<a href="#">Sunitinib (current access)</a>	Cap 37.5 mg
<a href="#">Sunitinib (widened access)</a>	Cap 12.5 mg Cap 25 mg Cap 37.5 mg Cap 50 mg
<a href="#">Valganciclovir (widened access)</a>	Tab 450 mg

Fenofibrate cap/tab 48 mg and 145 mg have been tendered as a potential funded alternative to gemfibrozil, [following notification of the delisting of gemfibrozil](#).

#### Data estimates for PCT injectable products included in the 2020/21 ITT

PHARMAC makes no representation as to the accuracy of this information or as to the level of sales or likely sales and, while PHARMAC has taken all reasonable care in preparing the information set out below, it accepts no liability for any errors or omissions in the information.

In order to be fair to all suppliers, we are unlikely to provide any further data relating to tender items while the 2020/21 ITT remains open.

#### Usage data for PCT injectable products

Chemical	Total usage (mg) <sup>1</sup>
Azacitidine	370,423
Bendamustine	311,756
Bleomycin Sulphate	8,208,273,000*
Carboplatin	2,013,908
Cisplatin	137,868
Cyclophosphamide	6,134,574
Cytarabine	4,493,242
Doxorubicin	312,878

Epirubicin	82,099
Fluorouracil sodium	28,888,214
Idarubicin Hydrochloride	1,705
Irinotecan	955,641
Methotrexate	2,780,562
Oxaliplatin	783,467
Pemetrexed	1,061,695
<p><sup>1</sup>Usage in mg, for period between 1 January 2019 to 31 December 2019</p> <p>* Usage shown in IU (international units)</p> <p>These volumes are approximate and indicative only. PHARMAC makes no representation as to the accuracy of these figures or as to the level of sales or likely sales of any tender item.</p>	

### More information

If you have any queries regarding the tender or require any assistance with the e-portal please contact the Tender Analysts (Chippy Compton and Ollie Cox) at [tender@pharmac.govt.nz](mailto:tender@pharmac.govt.nz)